In this issue:
Brentuximab vedotin + chemo in Hodgkin lymphoma
Bosutinib vs imatinib in newly diagnosed CML
Guadecitabine in relapsed/ refractory AML
Genotype-specific MRD interpretation for stratifying paediatric ALL
Venetoclax for CLL progressing after ibrutinib
First-line brentuximab vedotin in Hodgkin lymphoma
Predictive value of MRD based on immunoglobulin/T-cell receptor and BCR/ABL1
Eltrombopag for advanced MDS/AML with severe thrombocytopenia
Single-agent ibrutinib in relapsed/refractory follicular lymphoma
Brentuximab vedotin + dacarbazine or bendamustine in elderly Hodgkin lymphoma
Please login below to download this issue (PDF)